Ventas stock trades on recurring income and 2025 growth

Ventas (US9227931050) remains a healthcare REIT built around senior housing, outpatient medical office and other care-linked real estate, with the latest report metrics pointing to steady cash-flow generation and portfolio scale. Its most recent results and investor materials frame the stock around recurring rent, occupancy trends and balance-sheet discipline rather than a single one-day catalyst.

Revenue and cash flow

The company reported $1.4 billion in revenue for the first quarter of 2026 and adjusted funds from operations per share of $0.84, both figures that anchor the current read-through for the shares. For full-year 2025, Ventas also reported $5.1 billion in revenue, giving investors a clear comparison point for how the business has grown through the cycle.

That comparison matters because the first quarter of 2026 came after a full year that already reached the $5.1 billion mark, so the current run rate can be judged against a large prior base. A quarter with $0.84 in adjusted FFO per share against a $5.1 billion revenue year is the kind of profile income investors watch closely in a REIT.

Margins and leverage

Ventas said its 2025 normalized funds from operations were $1.43 per share, while adjusted FFO per share for the first quarter of 2026 came in at $0.84. The company also reported net income attributable to common stockholders of $0.16 per diluted share for the first quarter of 2026, a gap that shows why REIT investors focus more on FFO than headline earnings.

The balance sheet remains part of the same story. Ventas reported net debt to adjusted EBITDA of 5.6x at the end of 2025, and that leverage level helps explain why the shares tend to trade as a cash-flow and refinancing story as much as an operating one.

2026 guidance

Management guided to 2026 normalized FFO per share of $1.76 to $1.82, which implies a tighter frame for the rest of the year than a simple one-quarter snapshot would suggest. The midpoint of that range, $1.79, gives the market a concrete benchmark for whether rent growth and occupancy trends are holding up.

For investors, the key comparison is straightforward: 2025 normalized FFO per share was $1.43, while 2026 guidance points to $1.76 to $1.82. That is a clear numerical step-up, and it is the sort of range that often decides whether a REIT trades on income stability or stalls on valuation.

Senior housing demand

Ventas has been leaning into its senior housing operating portfolio, where occupancy and pricing can move more quickly than in longer-lease property types. The company’s 2025 and first-quarter 2026 results show that segment performance is central to the investment case, especially as demographic demand and operating efficiency feed through to cash flow.

The product focus is not a consumer product but a real estate platform, and the representative asset base is still the senior housing portfolio that helps drive the company’s FFO. That makes the operating mix more important than headline property count alone.

Shares and valuation

On the market side, Ventas stock trades on the New York Stock Exchange under the ticker NYSE: VTR, and the stock remains a U.S. healthcare REIT rather than a broad market cyclical. As of 22 July 2026, the market cap line and a live price were not available in the search set, so the valuation picture is best read through the company’s dated operating figures and guidance instead.

That still leaves investors with a useful frame: 2025 revenue of $5.1 billion, first-quarter 2026 revenue of $1.4 billion, and 2026 normalized FFO guidance of $1.76 to $1.82 per share. Those three numbers are enough to show why the shares are being judged on cash generation, not just growth optics.